Commission To Look Into 'Skyrocketing' EU Drug Prices, Availability, and Patient Access
Executive Summary
The European Commission, at the request of member state health ministers, is to run an analysis of the effect of incentives such as data exclusivity and supplementary protection certificates on drug prices, availability and access to medicines. Ministers have also given their backing to further voluntary cooperation initiatives among countries to rein in what they see as the very high prices of some medicines.
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.